Head & Neck · 2012 · 12 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyCancer ImmunotherapyTargeted Cancer TherapyTargeted TherapyCell Survival AssaysCetuximab TherapyEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor Targeting LigandsTumor Growth MonitoringTumor Shrinkage AssessmentWestern Blot Analysis
BACKGROUND: Arming antibody with toxins is a new approach in cancer therapy. We evaluated the efficacy of cetuximab-ZZ-PE38 immunocomplex in killing cancer cells in vitro and inhibiting tumor growth in nude mice. METHODS: Several cancer cell lines and human foreskin fibroblasts were tested for epidermal growth factor receptor (EGFR) expression and cetuximab binding using Western blot assay, enzyme-linked immunosorbent assay (ELISA), and flow cytometry. Cell survival in vitro was estimated by XTT assay. Tumor size was measured twice a week. RESULTS: Cetuximab-ZZ-PE38 immunocomplex was significantly more effective in killing head and neck cancer cells than nonspecific IgG-ZZ-PE38 complex or free ZZ-PE38, whereas normal cells were not affected. Tumor treatment with immunocomplex resulted in tumor shrinkage. The immunocomplex was safe to mice at a therapeutic dosage of 0.25 mg/mL, whereas the dosage of 0.50 mg/mL induced liver toxicity. CONCLUSIONS: Cetuximab-ZZ-PE38 immunocomplex is a highly effective agent in killing EGFR-positive cancer cells and in tumor shrinkage.
21
James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology · 2009 · 2K citations
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Peter Bross, Julie Beitz, Gang Chen et al. · PubMed · 2001 · 861 citations
Christoph A. Ritter, Marianela Pérez-Torres, Cammie Rinehart et al. · Clinical Cancer Research · 2007 · 506 citations · Full text
Medicine, Oncology, Pharmacology +13